Welcome to our dedicated page for ARTELO BIOSCIENCES SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artelo Biosciences, Inc. filings document a clinical-stage pharmaceutical issuer with securities listed on Nasdaq and a pipeline centered on lipid-signaling modulation. Registration statements and amendments describe securities offerings, delayed or continuous offering registration mechanics, common stock, warrants, pre-funded warrants and capital-structure terms.
Artelo's Form 8-K filings record material events including Nasdaq continued-listing compliance, annual-meeting matters, private-placement activity, material agreements, and clinical or regulatory disclosures for programs such as ART27.13 and ART26.12. The filings connect formal governance and financing records with updates on the company's drug-development strategy and intellectual-property activity.
Artelo Biosciences granted director Connie Matsui a stock option covering 136 shares of common stock at an exercise price of $1.15 per share, expiring on July 17, 2036. The option vests 100% on the earlier of the one-year anniversary of the July 17, 2026 Vesting Commencement Date or the day prior to the next annual stockholders’ meeting following that date, contingent on her continued service as a Service Provider.
ARTELO BIOSCIENCES granted director Douglas Blayney a stock option for 136 shares of common stock at an exercise price of $1.15 per share, expiring on July 17, 2036. The option vests 100% on the earlier of one year after the Vesting Commencement Date of July 17, 2026, or the day prior to the next annual stockholders’ meeting, subject to continued service.
Artelo Biosciences director Gregory Reyes received a grant of stock options covering 136 shares of common stock at an exercise price of $1.15 per share, expiring July 17, 2036. All options vest 100% on the earlier of one year after the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholder meeting, subject to his continued service.
Artelo Biosciences director Robert Martin received a grant of 136 stock options to purchase common stock at an exercise price of $1.15 per share. These options expire on July 17, 2036 and will vest 100% on the earlier of the one-year anniversary of the July 17, 2026 Vesting Commencement Date or the day prior to the next annual stockholders’ meeting after that date, subject to his continued service as a Service Provider under the issuer’s plan. Following this award, he holds 136 options from this grant, and the transaction is flagged as made pursuant to a Rule 10b5-1 trading arrangement.
ARTELO BIOSCIENCES, INC. reported that director Steven Kelly received a grant of stock options for 136 shares of common stock at an exercise price of $1.15 per share. The options vest 100% on the earlier of the one-year anniversary of a July 17, 2026 vesting commencement date or the day prior to the next annual stockholder meeting following that date, subject to continued service as a Service Provider, and expire on 2036-07-17.
Artelo Biosciences director Tamara A. Favorito received a grant of stock options covering 136 shares of common stock at an exercise price of $1.15 per share. The options expire on July 17, 2036 and will fully vest, subject to her continuing as a Service Provider, on the earlier of one year after the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholders’ meeting following that date. After this grant, she directly holds 136 stock options.
Artelo Biosciences, Inc. reported the results of its Annual Meeting of Stockholders held on July 17, 2026. As of the May 22, 2026 record date, 2,848,540 shares of common stock were outstanding, and 1,172,203 shares were represented at the meeting, approximately 41.2% of shares entitled to vote.
Stockholders cast votes for three director nominees: Gregory R. Reyes, M.D., Ph.D. (179,416 For; 55,405 Withhold; 937,382 broker non-votes), Tamara A. Favorito (176,821 For; 58,000 Withhold; 937,382 broker non-votes), and Gregory D. Gorgas (171,567 For; 63,254 Withhold; 937,382 broker non-votes). Two additional matters received 985,717 For, 164,845 Against, 21,641 Abstain on one proposal, and 91,158 For, 65,155 Against, 78,508 Abstain, with 937,382 broker non-votes, on another.
Artelo Biosciences is asking shareholders to approve Proposal 3 to comply with Nasdaq Listing Rule 5635(d) so the company may issue more than 20% of its issued and outstanding common stock under an existing Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5. The EPA gives the company the option to sell up to $25.0 million initially, with a Company‑discretionary increase up to a $50.0 million maximum commitment. Shares to Square Gate may be sold under specific volume and pricing mechanics tied to VWAP and other limits; the EPA included the issuance of 97,466 shares as consideration valued at $500,000 on January 30, 2026. The Board recommends a FOR vote; approval requires a majority of votes cast on Proposal 3.
Artelo Biosciences, Inc. is asking stockholders to approve several items at its 2026 virtual annual meeting. The proxy seeks election of three Class III directors — Gregory R. Reyes, M.D., Ph.D., Tamara A. Favorito and President and CEO Gregory D. Gorgas — to serve until the 2029 meeting. It also asks stockholders to amend the Articles of Incorporation to increase authorized common shares from 166,666,667 to 500,000,000, following a 1-for-3 reverse stock split effective March 9, 2026. As of the May 22, 2026 record date, 2,848,540 common shares were outstanding, with directors and executive officers as a group holding 93,282 shares, or 3.2%. The filing details board independence, committee structures, director compensation and executive pay, including $1.22 million in 2025 total compensation for Mr. Gorgas and the appointment and compensation of new CFO Mark E. Spring.